Quratis Inc.
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74 (NCT06714513) | Quratis Inc. | 2025-05-09 |
| Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19) (NCT05876364) | Quratis Inc. | 2021-11-19 |
| Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent (NCT03806699) | Quratis Inc. | 2019-04-02 |
| Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers (NCT03806686) | Quratis Inc. | 2018-05-31 |
Track Quratis Inc. automatically
Every clearance here is in the API, with alerts when new ones post.